Clinical-stage company ImmunoCellular Therapeutics has named Andrew Gengos as the company's president, chief executive officer and board member.
Gengos has served several companies and gained experience in areas such as corporate strategy, business development and transactions.
ImmunoCellular founder and chief scientific officer John Yu said, "ImmunoCellular's board of directors and management team are confident that Andrew's integrity, leadership qualities and breadth of experience in directing corporate strategy, forging successful partnerships and establishing alliances with the financial, business, medical and patient communities are exactly the mix of skills and attributes to advance our company to its next stages of maturation and value creation."
Gengos most recently served as president and chief executive officer of Neuraltus Pharmaceuticals, prior to that he served Amgen as vice president, strategy and corporate development.
